All forwardlooking statements speak only as of the date of this news release. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as may, will, should, likely, expects, anticipates, estimates, believes or plans, or comparable terminology, are forwardlooking statements. These hormone therapy products to treat both men and women. BioSantes lead products include BioEGelTM bioidentical estradiol gel for the treatment of female sexual dysfunction FSD.

The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as may, will, should, likely, expects, anticipates, estimates, believes or plans, or comparable terminology, are forwardlooking statements. All forwardlooking statements speak only as of the date of this news release. The company also is developing its calcium phosphate nanotechnology CAP for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.

Forwardlooking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forwardlooking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSantes filings with the Securities and Exchange Commission, including those factors discussed on pages to of BioSantes Form 10KSB, which discussion also is incorporated herein by reference. Additional information is available online at www. biosantepharma. com.

Forwardlooking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forwardlooking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSantes filings with the Securities and Exchange Commission, including those factors discussed on pages to of BioSantes Form 10KSB, which discussion also is incorporated

Related Blogs

  • Related Blogs on nanotechnology